Sign In
Buy EIGR
$1.73
+0 (+0%)
At Close: Aug 27, 2024
Eiger to Present at Jefferies 2019 London Healthcare Conference
01:00pm, Friday, 15'th Nov 2019
PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases
- 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve > 2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , .
Xconomy: Alder BioPharma’s Schatzman Steps Down as CEO by “Mutual Decision”
11:09pm, Tuesday, 20'th Mar 2018
Alder BioPharmaceuticals is now looking for a new chief executive, just as the company readies plans to file for FDA approval of its lead drug for
